Spero Therapeutics Q3 net loss widens on SP001 licensing payment
Overview
US biopharma firm's Q3 revenue fell to zero from $5.4 mln a year earlier
Net loss for Q3 widened to $44.3 mln, mainly due to $35 mln SP001 licensing payment
Company ended Q3 with $107.9 mln cash, expects runway into H2 2029
Outlook
Spero expects to initiate Phase 2 study for SP001 in IgG4-RD in Q2 2027
Company says cash and equivalents expected to fund operations into second half of 2029
Company continues to evaluate additional indications for SP001 beyond IgG4-RD
Result Drivers
SP001 LICENSING PAYMENT - Q3 R&D expenses rose mainly due to $35 mln upfront payment for SP001 licensing
Company press release:
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Net Loss | $44.28 mln | $27.50 mln (2 Analysts) | |
Q3 Income From Operation | -$41.91 mln | ||
Q3 Operating Expenses | $41.91 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Spero Therapeutics, Inc. is $6.00, about 488.2% above its November 11 closing price of $1.02
Reuters Recommended Reads
Nov 10 - Liquidia Q3 loss widens on litigation charge, negating Yutrepia demand
Nov 12 - Altimmune posts higher than expected Q3 loss
Nov 10 - Cellectar Biosciences Q3 net loss widens on higher R&D costs
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)